Parenteral Drugs (India) Ltd

Parenteral Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Parenteral Drugs (India) Ltd

₹ 2.90 -10.49%
21 Aug 2023
pdindia.com BSE: 524689 NSE: PDPL
About

Incorporated in 1983, Parenteral Drugs Ltd
is engaged in Manufacturing and Trading of Pharmaceutical Products

Key Points

Product Profile:[1]
a) IV Fluids:[2] Carbohydrate and Electrolytes, Diuretics, Dialysis & Irrigation Solution, Anti-infective & Anti-fungal
b) Oncology:[3] Injections, Tablets and Capsules
c) Anaesthesia:[4] Sevoplan, Isoplan

Website BSE NSE - BZ
  • Market Cap ₹ 8.65 Cr.
  • Current Price ₹ 2.90
  • High / Low ₹ /
  • Stock P/E
  • Book Value ₹ -276
  • Dividend Yield 0.00 %
  • ROCE %
  • ROE %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -30.3% over past five years.
  • Contingent liabilities of Rs.135 Cr.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
4 9 7 7 9 3 5 2 3 3 2 1 2
12 13 11 10 13 9 11 5 -1 6 6 5 8
Operating Profit -8 -4 -4 -3 -4 -6 -6 -3 3 -3 -3 -3 -6
OPM % -207% -45% -49% -41% -44% -199% -139% -140% 132% -89% -138% -222% -323%
0 0 0 0 0 0 0 0 0 0 0 0 52
Interest 25 26 27 28 29 30 31 32 32 34 35 37 0
Depreciation 55 4 4 4 4 4 4 4 4 4 4 4 27
Profit before tax -88 -34 -35 -35 -37 -40 -42 -39 -33 -41 -43 -44 19
Tax % -18% -19% -19% -26% -13% -19% -19% -21% -26% -22% -22% -22% -24%
-72 -28 -28 -26 -32 -32 -34 -31 -25 -32 -34 -35 24
EPS in Rs -24.13 -9.29 -9.49 -8.77 -10.71 -10.81 -11.29 -10.39 -8.33 -10.75 -11.27 -11.58 7.99
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
378 223 187 186 176 149 52 33 33 32 12 9
334 214 209 227 163 196 87 49 50 47 24 24
Operating Profit 44 9 -22 -40 13 -47 -35 -16 -16 -15 -12 -15
OPM % 12% 4% -12% -22% 7% -32% -66% -48% -50% -46% -97% -174%
1 0 0 57 0 1 2 1 0 0 0 52
Interest 23 39 42 54 59 58 74 86 96 110 125 106
Depreciation 11 13 17 18 24 17 19 19 69 17 17 40
Profit before tax 12 -43 -82 -55 -70 -121 -125 -119 -181 -142 -154 -109
Tax % 26% 11% 4% 7% -23% -10% -9% -20% -18% -20% -21% -30%
9 -48 -85 -59 -54 -108 -114 -96 -148 -114 -122 -76
EPS in Rs 3.37 -18.49 -32.94 -19.69 -18.14 -36.39 -38.26 -32.23 -49.60 -38.26 -40.82 -25.61
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -28%
5 Years: -30%
3 Years: -36%
TTM: -30%
Compounded Profit Growth
10 Years: %
5 Years: -3%
3 Years: 4%
TTM: -6%
Stock Price CAGR
10 Years: -18%
5 Years: 1%
3 Years: -11%
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity Capital 26 26 26 30 30 30 30 30 30 30 30 30
Reserves 289 256 171 119 65 247 -41 -138 -477 -591 -713 -854
258 277 368 429 464 601 637 639 637 635 635 116
77 87 68 68 74 32 134 233 349 477 615 1,191
Total Liabilities 650 646 632 646 634 910 760 764 539 550 567 483
242 338 328 320 299 653 634 617 356 339 322 205
CWIP 74 0 0 0 0 0 0 0 0 0 0 0
Investments 140 140 140 140 139 139 3 3 3 3 3 3
194 168 164 186 196 118 123 145 180 209 242 275
Total Assets 650 646 632 646 634 910 760 764 539 550 567 483

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
79 -5 -156 -21 -5 31 121 148 456 112 125 -0
-101 -35 -7 -10 -2 -109 -0 -1 0 0 0 65
17 42 161 31 3 78 -121 -148 -456 -112 -125 -64
Net Cash Flow -5 3 -2 0 -4 0 0 -0 0 0 -0 -0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 75 112 151 228 271 209 401 4 0 0 0 0
Inventory Days 116 171 113 155 234 45 34 67 224 73 103 69
Days Payable 92 196 122 102 230 51 187 733 671 458 504 71,797
Cash Conversion Cycle 99 87 142 281 274 202 247 -661 -446 -385 -401 -71,728
Working Capital Days 100 112 177 213 169 -20 -1,226 -3,761 -8,918 -10,755 -32,282 -47,898
ROCE % 6% -1% -7% -0% -2% -9% -7% -6% -24% -24% -238%

Shareholding Pattern

Numbers in percentages

Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022
73.28% 73.28% 73.28% 73.28% 73.28% 73.28% 73.28% 73.28% 73.28% 73.28% 73.28% 73.29%
0.01% 0.01% 0.03% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
26.71% 26.71% 26.69% 26.71% 26.71% 26.71% 26.71% 26.71% 26.71% 26.71% 26.71% 26.71%
No. of Shareholders 7,3967,3787,3307,2967,2957,3007,3007,2697,2057,1837,1647,129

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports